Open Payments Act AKA the ‘Sunshine Act’ Open Payments Act AKA the ‘Sunshine Act’ Public Postings of Physician Ownership, Investments, & Transfers of Value.

Slides:



Advertisements
Similar presentations
VCOM Conflict of Interest Policy Overview of Financial Conflict of Interest Related to Research December 4, 2013.
Advertisements

Financial Conflict of Interest July 2012 rev
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
Conflict of Interest (COI) Objectives: Provide an overview of financial conflict of interest (FCOI) related to research activities at Gillette Describe.
1 UMass Dartmouth Conflicts of Interest Policies UMass Dartmouth Liz Rodriguez February 17, 2011.

Physician Payment Sunshine Act
JUNE 19, 2012 PAUL MURPHY, JD DIRECTOR, RESEARCH ADMINISTRATION SERIES 2, SESSION 7 APPLICANTS & ADMINISTRATORS PREAWARD LUNCHEON SERIES Public Health.
National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships Rev. 10/21/2014 APGO Interaction with Industry: A Medical.
Personal financial benefit or economic interest from one’s position that may inappropriately: influence the employee’s judgment compromise the employee’s.
Commercial support is defined as financial or in- kind contributions given by a commercial interest, which is used to pay all or part of the costs of a.
Presented by: David E. Broome, Jr. Vice Chancellor and General Counsel Carl P.B. Mahler, II Executive Director, Office of Technology Transfer October 30,
O PEN P AYMENTS An Explanation of Section 6002 of the Affordable Care Act Center for Program Integrity September, 2013 CMS Disclaimer: This information.
ACC and the Physician Payments Sunshine Act. Disclaimers Information provided in this presentation is for educational purposes only and should not be.
1 Physician-Industry Transparency: The U.S. Physician Payment Sunshine Act.
1 Overview of Ethics Requirements for Employees of Montgomery County This is a summary to help identify issues; it is not the law. Please address ethics.
Conflicts of Interest in Research: Policies and Regulations Marie Barron, M.A., COI Program Specialist Rick Lyons, M.D., Ph.D., COI Committee C Chair.
1 UCDHS Vendor Relations Policy Development & Implementation Teresa Porter, CHC - Chief Compliance Officer David Levine, JD - Legal Counsel Allan Siefkin,
Conflicts of Interest James G. Anderson, Ph.D. Department of Sociology & Anthropology.
Identification & Distinction of Clinical Trial Participant Charges Bethany Martell Office of Clinical Research Associate Director- Financial Operations.
Promoting Objectivity in Research by Managing, Reducing, or Eliminating Conflicts of Interest UT HOP UT HOP The University of Texas at Austin.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
ECOI electronic Conflict of Interest User Guide 1 Emory University, Office of Research Administration.
VCU School of Medicine Policy on Industry Relations Effective July 1, 2009.
Office of Regulatory Affairs  Institutional Conflict of Interest - Clinical Trials Committee (ICOI-CT)  Reviews research conflicts that arise…
Research Conflicts of Interest: Identifying and Minimizing COI from the Perspectives of Sponsors, Faculty and the IRB Research Conflicts of Interest: Identifying.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
1 Long-term Care Vermont’s Approach Individual Supports Unit Division of Disability and Aging Services Department of Disabilities, Aging & Independent.
Sunshine Act Clinical Faculty Meeting August 14, 2014.
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
1 Colorado Bar Association Health Law Section April 20, 2013 CMS Physician Payment Sunshine Act Final Rule: Sunshine or Black Hole? Michael M. Schmidt.
CONFLICTS OF INTEREST PRESENTED BY THE UMMC OFFICE OF INTEGRITY AND COMPLIANCE.
CME Under Fire THOMAS SULLIVAN President Rockpointe Corporation March 6, 2009.
OPEN PAYMENTS UF College of Medicine Brown Bag July 23, 2013 Gary Wimsett, Jr., JD.
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
WHAT STAKEHOLDERS NEED TO KNOW ABOUT THE CME/SUNSHINE ACT PROVISION OF THE ‘21 ST CENTURY CURES ACT’ JULY 14,
Managing Conflicts of Interest at the IRB and Institutional Level: INSTITUTIONAL CONFLICTS OF INTEREST Claudia R. Adkison, J.D., Ph.D. Executive Associate.
Faculty Council on Research April 11, 2012 Jeff Cheek, Ph.D. UW Associate Vice Provost for Research Compliance and Operations New PHS regulations on financial.
New Federal Policy on Financial Conflicts of Interest Matt Richter, MA, JD anticipated 2012 COI Program Specialist Office of Research Policy
Partners Conflict of Interest Policy and Reporting October 11, 2012.
An Educational Session on HSC OP 10.27, Health Care Vendor Interactions April 20, 2009.
Copyright © Harvard Medical School. All Rights Reserved. Outside Activity Report: What Do I Need to Report?
Stanford Policy – Faculty ◦ Mission: Promote public good by transferring knowledge  Consulting  Technologies arising from research These activities can.
The Physician Payments Sunshine Act Legislation Ann Leopold Kaplan October 27, 2008.
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
Compensation Plan & Incentive Pay Making Sense of X,Y, and Z New Faculty Orientation UCSF Radiology and Biomedical Imaging Session 1: September 17, 2014.
Disclosure of Financial Interest Policy. Medical Staff Policy Approved by the MEC’s Aimed at protecting the integrity of the LMHS Medical Staffs Requires.
Conflict of Interest in Research
eCOI electronic Conflict of Interest
Kyle Conner, MA, CIP Associate Director, Office of Human Research
Disclosure In relation to this presentation, I declare the following, real or perceived conflicts of interest: - A conflict of interest is any situation.
Kyle Conner, MA, CIP Associate Director, Office of Human Research
Conflict of Interest Disclosure
Conflict of Interest Disclosure
UW Conflict of Interest Program Manager Office of Research Policy
RxInsider Shannon Staton PharmD Candidate 2016
UCR PRO Reviewer Placemat
City Council Work Session
The Physician Payments Sunshine Act
Chapter 7 The Health Care System
An Introduction to the Sunshine Act
Disclosure of conflicts of interest – explanation
Conflict of Interest Disclosure
Conflict of Interest Disclosure
Disclosure of conflicts of interest
Disclosure of conflicts of interest
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Financial and Other Disclosures
Chapter 7The Health Care System
Presentation transcript:

Open Payments Act AKA the ‘Sunshine Act’ Open Payments Act AKA the ‘Sunshine Act’ Public Postings of Physician Ownership, Investments, & Transfers of Value on the Centers for Medicare & Medicaid Services Website Suzann VanNasdale, J.D. COI Administrator, Compliance Manager Office of Research Ohio State University Leeanne B. Walker, JD Director, Compliance & Research Integrity University of North Carolina School of Medicine June Anne Insco Outside Interests and COI Manager Office of Regulatory Affairs University of Michigan Medical School National Council of University Research Administrators

The ‘Sunshine Act’ is a New Regulation that Makes Public Physician-Industry Financial Relationships. 2 $ “There's a lot of skepticism about financial relationships between doctors and drug companies. Disclosure of those ties would help to build confidence that there's nothing to hide..” -- Senator Charles 2014 National Council of University Research Administrators

The Goal is to Shed Light on the Relationships Between Industry, Research, and Individual Medical Practices. 3 Lack of transparency created a culture that this law should begin to change substantially. Senator Grassley ~Interactions can create conflicts between the best interest of patients and the influence of gifts and favors on decisions. This website will enable consumers to make informed decisions. REFORM $ INFLUENCE DOCS INFORMED 2014 National Council of University Research Administrators

Manufacturers & Group Purchasing Organizations Must Report Financial Information to CMS. 4 REPORT ABOUT DOCS 2014 National Council of University Research Administrators

Companies Must Report Data about Licensed MDs*, DOs, Podiatrists, Optometrists, Chiropractors, Dental Surgeons, Dentists, and Teaching Hospitals. NOT *Residents Medical Students Nurses Physician Assistants Other Healthcare Providers 2014 National Council of University Research Administrators

Charitable contributions Compensation (e.g., Speaking) Consulting Fees Entertainment, Food, Gifts Grants Honoraria Ownership/Investments (includes interests of family members) Education Research Funding (includes Name of Teaching Hospital and Physician PIs) Royalties Travel CMS will Post Ownership, Investments, and ‘Transfers of Value’ worth $10* or cumulative values of >$ National Council of University Research Administrators

Important Dates First reporting period 8/1/13 to 12/31/13. Companies report data to CMS by 3/31/14. Physicians have 45 days to review starting August 1.* After the 45 days, CMS will allow another 15 days for dispute resolution. Public Posting September 30, 2014 (maybe) 2014 National Council of University Research Administrators

Companies can request a delay in publication of research information to protect R&D. – Information must still be reported. – Information will be posted when a new drug, device, etc. is approved by the FDA or in 4 years, whichever comes first National Council of University Research Administrators

What does this new rule have to do with COI and Sponsored Programs? 9

What are the biggest concerns of the faculty physicians? 10

What can physicians do to prepare? 11

What educational information is being provided for faculty? For patients? 12

Does your institution intend to assist its faculty with disputes? 13

Does your institution plan to use the data available on the CMS website? If so, how? 14

Appendix A Public Postings of Physician Compensation Data Applicable manufacturer’s name Physician’s Name Specialty Primary business address Amount of payment or other transfer of value in U.S. dollars Date of payment or other transfer of value Form of payment or other transfer of value Nature of payment or other transfer of value Name(s) of the related covered drugs, devices, biologicals, or medical supplies, as applicable National Drug Codes (NDCs) of related covered drugs and biologicals, if any Name of the entity that received the payment or other transfer of value, if not provided to the covered recipient directly Statement providing additional context for the payment or other transfer of value (optional) 2014 National Council of University Research Administrators

Appendix B Public Postings of Ownership & Investment Data Applicable manufacturer’s or GPO’s name Physician’s Name Specialty Primary business address Whether the interest is held by the physician or an immediate family member of the physician Dollar amount invested Value and terms of each ownership or investment interest Amount of payment or other transfer of value in U.S. dollars Date of payment or other transfer of value Form of payment or other transfer of value Nature of payment or other transfer of value Name(s) of the related covered drugs, devices, biologicals, or medical supplies, as applicable. National Drug Codes (NDCs) of related covered drugs and biologicals, if any* Name of the entity that received the payment or other transfer of value, if not provided to the physician directly Statement providing additional context for the payment or other transfer of value (optional) 2014 National Council of University Research Administrators

Appendix C—Public Postings of Research Data Name of research institution/entity receiving payment Total amount of research payment Name of study Name(s) of the related covered drugs, devices, biologicals or medical supplies NDCs of related covered drugs and biologicals, if any* Principal investigator(s): – Name – Specialty – Primary business address Context of research ClinicalTrials.gov identifier (optional) 2014 National Council of University Research Administrators

Appendix D—Categories of Payments, Ownership, and Investments Reportable to CMS Compensation for services other than consulting, including serving as faculty or as a speaker at an event other than a continuing education program Compensation for serving as faculty or as a speaker for a continuing education program Honoraria Consulting fee Royalty or license Current or prospective ownership or investment interest Grant Gift Entertainment Food and beverage Travel and lodging Education Charitable contribution 2014 National Council of University Research Administrators